Korean Firms Expand US Footprint: Beauty Brand Enters Costco, S-OIL Hires, MedTech Hits FDA Milestone

The Quick Take

• Korean skincare brand re:nk entered 50 US Costco physical stores, launching a new collagen cream product
• S-OIL (S-Oil) launched its 50th-anniversary white-collar hiring drive across strategy, finance, and engineering roles
• L&K Bio's FDA-approved cervical spine cage BluEX-C surpassed 50 cumulative US surgeries within months of launch

Three distinct Korean corporate milestones converged on October 8, illustrating the breadth of Korean enterprise expansion into the US market. Beauty brand re:nk's entry into 50 Costco physical locations follows prior online sell-outs of its skin creams, signaling a graduation from e-commerce-led entry to mainstream brick-and-mortar retail penetration. S-OIL, celebrating its 50th anniversary, launched a significant new hire campaign across its business strategy, finance, and engineering units, reflecting the petrochemical major's confidence in growth pipeline investments.

L&K Bio's achievement of 50 cumulative US surgical procedures for its FDA-approved cervical spine cage BluEX-C is the most commercially significant signal of the three: FDA approval was secured in May 2026, first clinical application followed in June, and 50 surgical levels were achieved in approximately three months — a rapid adoption pace for a spinal implant product. This speed of surgical uptake among US key opinion leaders suggests strong clinical acceptance and positions L&K Bio for broader hospital system adoption. Peer Korean medtech companies monitoring FDA entry timelines will benchmark against this ramp.

For investors tracking Korean corporate outbound growth, these milestones collectively represent premium consumer goods, energy, and medtech sectors all advancing US market positions simultaneously. The key variables are re:nk's Costco sell-through rate during Q4 2026 holiday season, S-OIL's ability to execute on its petrochemical expansion projects with new hires, and L&K Bio's pipeline of additional spine products awaiting FDA review. A sustained US consumer spending environment and stable FDA approval timelines are the macro-level prerequisites for continued Korean medtech and consumer brand expansion.

Synthesized from 3 sources.